Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Cullinan Therapeutics (NASDAQ:CGEM)

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Cullinan Therapeutics (NASDAQ:CGEM)

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations. Data will be presented at the European Society for Medical Oncology (ESMO) Congress 2025. The mini oral pr…

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor…